Cargando…

Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma

To develop a more precise risk-stratification system by investigating the prognostic impact of tumor growth within fatty tissues surrounding the kidney and/or renal vein. We conducted a retrospective review of the medical records of 211 patients with a pathologic diagnosis of T3aN0M0RCC among 4,483...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jong Jin, Lee, Jung Keun, Do Song, Byung, Lee, Hakmin, Lee, Sangchul, Byun, Seok-Soo, Lee, Sang Eun, Hong, Sung Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141461/
https://www.ncbi.nlm.nih.gov/pubmed/30224666
http://dx.doi.org/10.1038/s41598-018-32362-w
_version_ 1783355700776271872
author Oh, Jong Jin
Lee, Jung Keun
Do Song, Byung
Lee, Hakmin
Lee, Sangchul
Byun, Seok-Soo
Lee, Sang Eun
Hong, Sung Kyu
author_facet Oh, Jong Jin
Lee, Jung Keun
Do Song, Byung
Lee, Hakmin
Lee, Sangchul
Byun, Seok-Soo
Lee, Sang Eun
Hong, Sung Kyu
author_sort Oh, Jong Jin
collection PubMed
description To develop a more precise risk-stratification system by investigating the prognostic impact of tumor growth within fatty tissues surrounding the kidney and/or renal vein. We conducted a retrospective review of the medical records of 211 patients with a pathologic diagnosis of T3aN0M0RCC among 4,483 renal cell carcinoma (RCC) patients from February 1988 to December 2015 according to the number of T3a pathologies—extrarenal fat invasion (EFI) and/or renal venous invasion (RVI). During a mean follow-up duration of 38.8 months, the patients with both pathologies (EFI + RVI) had lower recurrence free survival (RFS) rate than those with only a single pathology (p = 0.001). Using multivariable Cox regression analysis, the presence of both factors was shown to be an independent predictor of RFS (HR = 1.964, p = 0.032); cancer specific survival rate was not different among patients with EFI and/or RVI. Patients with pathologic T3aN0M0 RCC presenting with both EFI and RVI were at an increased risk of recurrence following nephrectomy. Therefore, pathologic T3a RCC could be sub-divided into those with favorable and unfavorable disease according to presence of EFI and/or RVI pathologies.
format Online
Article
Text
id pubmed-6141461
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61414612018-09-20 Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma Oh, Jong Jin Lee, Jung Keun Do Song, Byung Lee, Hakmin Lee, Sangchul Byun, Seok-Soo Lee, Sang Eun Hong, Sung Kyu Sci Rep Article To develop a more precise risk-stratification system by investigating the prognostic impact of tumor growth within fatty tissues surrounding the kidney and/or renal vein. We conducted a retrospective review of the medical records of 211 patients with a pathologic diagnosis of T3aN0M0RCC among 4,483 renal cell carcinoma (RCC) patients from February 1988 to December 2015 according to the number of T3a pathologies—extrarenal fat invasion (EFI) and/or renal venous invasion (RVI). During a mean follow-up duration of 38.8 months, the patients with both pathologies (EFI + RVI) had lower recurrence free survival (RFS) rate than those with only a single pathology (p = 0.001). Using multivariable Cox regression analysis, the presence of both factors was shown to be an independent predictor of RFS (HR = 1.964, p = 0.032); cancer specific survival rate was not different among patients with EFI and/or RVI. Patients with pathologic T3aN0M0 RCC presenting with both EFI and RVI were at an increased risk of recurrence following nephrectomy. Therefore, pathologic T3a RCC could be sub-divided into those with favorable and unfavorable disease according to presence of EFI and/or RVI pathologies. Nature Publishing Group UK 2018-09-17 /pmc/articles/PMC6141461/ /pubmed/30224666 http://dx.doi.org/10.1038/s41598-018-32362-w Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Oh, Jong Jin
Lee, Jung Keun
Do Song, Byung
Lee, Hakmin
Lee, Sangchul
Byun, Seok-Soo
Lee, Sang Eun
Hong, Sung Kyu
Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma
title Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma
title_full Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma
title_fullStr Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma
title_full_unstemmed Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma
title_short Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma
title_sort accurate risk assessment of patients with pathologic t3an0m0 renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141461/
https://www.ncbi.nlm.nih.gov/pubmed/30224666
http://dx.doi.org/10.1038/s41598-018-32362-w
work_keys_str_mv AT ohjongjin accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma
AT leejungkeun accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma
AT dosongbyung accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma
AT leehakmin accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma
AT leesangchul accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma
AT byunseoksoo accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma
AT leesangeun accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma
AT hongsungkyu accurateriskassessmentofpatientswithpathologict3an0m0renalcellcarcinoma